A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).

David B. Page,Isaac Kim,Brie Chun,William L. Redmond,Maritza Martel,Motomi Mori,Dottie Wadell,Nicole Moxon,Staci L. Mellinger,Walter J. Urba,Ayca Gucalp,Tiffany A. Traina

A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).

2019

David B. Page
Isaac Kim
Brie Chun
William L. Redmond
Maritza Martel
Motomi Mori
Dottie Wadell
Nicole Moxon
Staci L. Mellinger
Walter J. Urba
Ayca Gucalp
Tiffany A. Traina

TPS1106Background: ICB (atezolizumab, anti-PD-L1) is known to improve survival when added to chemo, however only in PD-L1-positive, triple-negative MBC. ICB is less effective in hormone receptor po...

Keywords:

Androgen receptor
Blockade
Immunotherapy
Phases of clinical research
T cell
Cancer research
Immune checkpoint
Pathology
Medicine
Metastatic breast cancer
Hormone receptor
Atezolizumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations